Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?

2026-07-31
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.

Is The Sharp Drop In Hims & Hers Health Stock A Reason To Buy?

2026-07-30
The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.

Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026

2026-07-30
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.

LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Rise

2026-07-30
Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.

Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics

2026-07-30
Women who test positive for bacterial vaginosis (BV) were over three times more likely to also test positive for one or more non-viral sexually transmitted infections (STIs) than women who test negative for BV, according to a new Health Trends® study from Quest Diagnostics (NYSE: DGX) and Hologic, Inc.

Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs

2026-07-29
BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

2026-07-28
JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.

Equinix Stock Has A Message For Management

2026-07-27
The company raised its outlook on booming AI demand, but the stock is telling a different story by standing still.

Why Quest Diagnostics Stock Climbed This Past Week

2026-07-27
Demand for medical testing services is rising.

Why Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting Buybacks

2026-07-26
Earlier this week, Quest Diagnostics reported second-quarter 2026 results showing sales of US$3,043 million and diluted EPS of US$2.84, and raised its full‑year 2026 revenue guidance to US$11.95–US$12.05 billion and reported EPS to US$9.97–US$10.17. The company also continued its long-running capital return program, repurchasing 522,436 shares for US$100 million in the quarter, which supports earnings per share alongside higher‑value advanced diagnostics and growing test volumes. We’ll now...